Show simple item record

dc.contributor.authorSandvei, Marie Søfteland
dc.contributor.authorVatten, Lars Johan
dc.contributor.authorBjelland, Elisabeth Krefting
dc.contributor.authorEskild, Anne
dc.contributor.authorHofvind, Solveig
dc.contributor.authorUrsin, Giske
dc.contributor.authorOpdahl, Signe
dc.date.accessioned2019-03-14T08:33:16Z
dc.date.available2019-03-14T08:33:16Z
dc.date.issued2018-08-06
dc.description.abstractIt is not known whether increased breast cancer risk caused by menopausal hormone therapy (HT) depends on body mass patterns through life. In a prospective study of 483,241 Norwegian women aged 50–69 years at baseline, 7656 women developed breast cancer during follow-up (2006–2013). We combined baseline information on recalled body mass in childhood/adolescence and current (baseline) body mass index (BMI) to construct mutually exclusive life-course body mass patterns. We assessed associations of current HT use with breast cancer risk according to baseline BMI and life-course patterns of body mass, and estimated relative excess risk due to interaction (RERI). Within all levels of baseline BMI, HT use was associated with increased risk. Considering life-course body mass patterns as a single exposure, we used women who “remained at normal weight” through life as the reference, and found that being “overweight as young” was associated with lower risk (hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.76–0.94), whereas women who “gained weight” had higher risk (HR 1.20, 95% CI 1.12–1.28). Compared to never users of HT who were “overweight as young”, HT users who either “remained at normal weight” or “gained weight” in adulthood were at higher risk than expected when adding the separate risks (RERI 0.52, 95% CI 0.09–0.95, and RERI 0.37, 95% CI − 0.07–0.80), suggesting effect modification. Thus, we found that women who remain at normal weight or gain weight in adulthood may be more susceptible to the risk increasing effect of HT compared to women who were overweight as young.en_US
dc.descriptionAccepted manuscript version. Published version available at <a href=https://doi.org/10.1007/s10654-018-0431-7> https://doi.org/10.1007/s10654-018-0431-7</a>.en_US
dc.identifier.citationSandvei, M.S., Vatten, L.J., Bjelland, E.K., Eskild, A., Hofvind, S., Ursin, G. & Opdahl, S. (2018). Menopausal hormone therapy and breast cancer risk: effect modification by body mass through life. <i>European Journal of Epidemiology</i>. https://doi.org/10.1007/s10654-018-0431-7en_US
dc.identifier.cristinIDFRIDAID 1607460
dc.identifier.doi10.1007/s10654-018-0431-7
dc.identifier.issn0393-2990
dc.identifier.issn1573-7284
dc.identifier.urihttps://hdl.handle.net/10037/14971
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.relation.journalEuropean Journal of Epidemiology
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectBreast canceren_US
dc.subjectMenopausal hormone therapyen_US
dc.subjectBody-mass indexen_US
dc.subjectepidemiologyen_US
dc.subjectCohort studyen_US
dc.subjectVDP::Medical disciplines: 700::Health sciences: 800::Epidemiology medical and dental statistics: 803en_US
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800::Epidemiologi medisinsk og odontologisk statistikk: 803en_US
dc.titleMenopausal hormone therapy and breast cancer risk: effect modification by body mass through lifeen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record